Morepen Laboratories (NSE:MOREPENLAB) Cyclically Adjusted PB Ratio: (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
73 GF Score
Price ₹73.46
GF Value ₹54.25
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Morepen Laboratories Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Morepen Laboratories  (NSE:MOREPENLAB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Morepen Laboratories Cyclically Adjusted PB Ratio Related Terms


Morepen Laboratories Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Morepen Laboratories Cyclically Adjusted PB Ratio Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.76 2.55

Morepen Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 3.76 0.00 2.55 0.00

NSE:MOREPENLAB vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morepen Laboratories Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Morepen Laboratories's Cyclically Adjusted PB Ratio falls into.


NSE:MOREPENLAB
73GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Morepen Laboratories Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Morepen Laboratories's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Morepen Laboratories's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/166.1454*166.1454
=0.000

Current CPI (Jun. 2026) = 166.1454.

Morepen Laboratories Quarterly Data

Book Value per Share CPI Adj_Book
201503 6.391 97.163 10.928
201603 3.851 102.518 6.241
201703 4.363 105.196 6.891
201706 0.000 107.109 0.000
201709 0.000 109.021 0.000
201712 0.000 109.404 0.000
201803 5.023 109.786 7.602
201806 0.000 111.317 0.000
201809 5.246 115.142 7.570
201812 0.000 115.142 0.000
201903 5.626 118.202 7.908
201906 0.000 120.880 0.000
201909 5.860 123.175 7.904
201912 0.000 126.235 0.000
202003 6.315 124.705 8.414
202006 0.000 127.000 0.000
202009 7.359 130.118 9.397
202012 0.000 130.889 0.000
202103 9.443 131.771 11.906
202106 0.000 134.084 0.000
202109 10.943 135.847 13.384
202112 0.000 138.161 0.000
202203 12.108 138.822 14.491
202206 0.000 142.347 0.000
202209 14.415 144.661 16.556
202212 0.000 145.763 0.000
202303 14.729 146.865 16.663
202306 0.000 150.280 0.000
202309 15.435 151.492 16.928
202312 0.000 152.924 0.000
202403 16.574 153.035 17.994
202406 0.000 155.789 0.000
202409 20.265 157.882 21.326
202412 0.000 158.323 0.000
202503 21.101 157.552 22.252
202506 0.000 159.755 0.000
202509 21.831 162.289 22.350
202512 0.000 163.281 0.000
202603 22.747 164.272 23.006
202606 0.000 166.145 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹73.46 is trading 35.4% above its estimated GF Value™ of ₹54.25. GuruFocus considers Morepen Laboratories to be Significantly Overvalued.

Key valuation signals for NSE:MOREPENLAB:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹54.25 vs. price of ₹73.46 (35.4% above fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
73GF Score

Get the complete analysis for NSE:MOREPENLAB

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹73.46
Price
₹54.25
GF Value